Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$48.66 USD
-0.63 (-1.28%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $48.66 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CYTK 48.66 -0.63(-1.28%)
Will CYTK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CYTK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CYTK
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
Company News for Sep 3, 2025
CYTK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Camzyos Strengthen BMY's Cardiovascular Portfolio?
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
Techne (TECH) Beats Q4 Earnings and Revenue Estimates
Other News for CYTK
CYTK forms 1,2,3 Pullback Bullish on September 18
Cytokinetics Faces Lawsuit Over Misleading Investors
CYTK forms MACD Bearish Signal Line Cross on September 18
Cytokinetics (CYTK) Rises on Convertible Note Offering Plan
Morning Movers: Workday surges after Elliot stake, stock buyback program